EN PT


0133/2017 - Incorporation of new medicines by the National Commission for Incorporation of Technologies, 2012 to June 2016
Incorporação de novos medicamentos pela Comissão Nacional de Incorporação de Tecnologias do SUS, 2012 a junho de 2016

Author:

• Rosângela Caetano - Caetano, Rosângela - Universidade do Estado do Rio de Janeiro, Politicas, Planejamento e Administração em Saúde Rio de Janeiro - <caetano.r@gmail.com> +

Co-author(s):

• Rondineli Mendes da Silva - Silva, R.M. - Escola Nacional de Saúde Pública Sérgio Arouca (ENSP), Núcleo de Assistência Farmacêutica - <rondineli.mendes@gmail.com>
ORCID: https://orcid.org/0000-0002-6243-5179
• Érica Militão Pedro - Pedro, Érica Militão - Universidade do Estado do Rio de Janeiro - <erica_farmacia2011@yahoo.com.br>
• Ione Ayala Gualandi de Oliveira - Oliveira, I.A.G. - Universidade do Estado do Rio de Janeiro - <ionegualandi@yahoo.com.br>
• Aline Navega Biz - Biz, Aline Navega - Universidade do Estado do Rio de Janeiro - <alinebiz@gmail.com>
• Pamela Santana - Santana, Pamela - Universidade do Estado do Rio de Janeiro - <pamelakguimaraes@yahoo.com.br>

Thematic Area:

Não Categorizado

Abstract:

The National Commission for incorporation of Health Technologies (CONITEC), established in 2011, advises the Ministry of Health in decisions related to the incorporation, exclusion or change of medicines, products and procedures in the Unified Health System (SUS). The study investigated the decision-making process, profile of demands and incorporation of new medicines in the SUSJanuary/2012 to June/2016, based on data available on the CONITEC website. All submissions were evaluated and characterized by technology and applicant type. The incorporations were analyzed according to the Anatomical-Therapeutic-Chemical classification, International Classification of Disease of the clinical indication and active record in the National Health Surveillance Agency. In the period, 485 submissions were received, 92.2% concerning requests for incorporation and 62.1% for medicines, of which 93 (30.1%) received a favorable recommendation for incorporation. Domestic demands were more successful than externally originated ones. Six unregistered drugs were incorporated. Infectious and parasitic diseases and musculoskeletal diseases constituted the main clinical indications. The recommendation of incorporation occurred mainly based on the additional clinical benefits and low budget impact.

Keywords:

MedicinesHealth Technology AssessmentDecision MakingUnified Health System

Content:

Access Issue in Scielo

Other languages:







How to

Cite

Caetano, Rosângela, Silva, R.M., Pedro, Érica Militão, Oliveira, I.A.G., Biz, Aline Navega, Santana, Pamela. Incorporation of new medicines by the National Commission for Incorporation of Technologies, 2012 to June 2016. Cien Saude Colet [periódico na internet] (2017/Mar). [Citado em 10/05/2025]. Está disponível em: http://cienciaesaudecoletiva.com.br/en/articles/incorporation-of-new-medicines-by-the-national-commission-for-incorporation-of-technologies-2012-to-june-2016/16179



Execution



Sponsors